Zusammenfassung
Die Strategien zur Risikostratifizierung und risikoadaptierten Diagnostik und Therapie von Patienten mit Lungenembolie befinden sich aktuell in einer Phase des Umbruchs. Für die neuen europäischen Leitlinien, die im Jahr 2014 erscheinen sollen, werden umfangreiche Veränderungen insbesondere im Bereich der Indikation zur Thrombolyse bei normotensiven Patienten mit „intermediärem“ Risiko, der interventionellen Hybridverfahren zur pharmakomechanischen lokalen Thrombolyse, der neuen oralen Antikoagulanzien zur Therapie und (verlängerten) Sekundärprophylaxe, der möglichen Indikation von Azetylsalizylsäure zur verlängerten Sekundärprophylaxe sowie der ambulanten Behandlung von Patienten mit „niedrigem“ Risiko erwartet. In diesem Artikel werden die aktuellen Leitlinien zur Therapie und Sekundärprävention der Lungenembolie sowie die aktuelle klinische Studienlage und deren mögliche Implikationen für die Therapie und die Sekundärprävention der Lungenembolie zusammengefasst.
Abstract
Currently strategies for risk stratification and risk-adjusted diagnostics and management algorithms of patients with pulmonary embolism are undergoing considerable progress and transition. For the new European guidelines expected in 2014, extensive changes are expected in the areas of (1) thrombolysis of normotensive patients with intermediate risk, (2) interventional ultrasound-enhanced low-dose catheter-derived (pharmacomechanical) local thrombolysis, (3) novel oral anticoagulants for therapy and (extended) secondary prophylaxis, (4) possible indications of low-dose aspirin for extended secondary prophylaxis and (5) home treatment of patients with low risk pulmonary embolism. This article summarizes the current guidelines for therapy and secondary prophylaxis of pulmonary embolism and novel clinical studies and the possible implications for therapy and secondary prophylaxis of pulmonary embolism.
Literatur
Kucher N, Rossi E, De Rosa M, Goldhaber SZ (2006) Massive pulmonary embolism. Circulation 113:577–582
Wood KE (2002) The presence of shock defines the threshold to initiate thrombolytic therapy in patients with pulmonary embolism. Intensive Care Med 28:1537–1546
Kasper W, Konstantinides S, Geibel A et al (1997) Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 30:1165–1171
Grifoni S, Olivotto I, Cecchini P et al (2000) Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 101:2817–2822
Kasper W, Konstantinides S, Geibel A et al (1997) Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 77:346–349
Ribeiro A, Lindmarker P, Juhlin-Dannfelt A et al (1997) Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 134:479–487
Torbicki A, Perrier A, Konstantinides SV et al (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29:2276–2315
Jaff MR, McMurtry MS, Archer SL et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123:1788–1830
Hach-Wunderle V (2010) Interdisziplinäre S2-Leitlinie: Diagnostik und Therapie der Bein- und Beckenvenenthrombose und der Lungenembolie. Vasa 39:1–39
Wells PS, Anderson DR, Rodger M et al (2001) Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135:98–107
Le Gal G, Righini M, Roy PM et al (2006) Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 144:165–171
Stein PD, Chenevert TL, Fowler SE et al (2010) Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 152:434–443
Konstantinides S, Goldhaber SZ (2012) Pulmonary embolism: risk assessment and management. Eur Heart J 33(24):3014–3022
Meneveau N, Seronde MF, Blonde MC et al (2006) Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 129:1043–1050
Stein PD, Matta F (2012) Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 125:465–470
Stein PD, Matta F, Steinberger DS, Keyes DC (2012) Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism. Am J Med 125:50–56
Hach-Wunderle V (2005) Interdisziplinäre S2-Leitlinie: Diagnostik und Therapie der Bein- und Beckenvenenthrombose und der Lungenembolie. Vasa 34(Suppl 66):1–24
Sharifi M, Bay C, Skrocki L et al (2012) Moderate pulmonary embolism treated with thrombolysis (from the „MOPETT“ Trial). Am J Cardiol 111:273–277
The PEITHO Steering Committee (2012) Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 163:33–38
Kuo WT, Gould MK, Louie JD et al (2009) Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 20:1431–1440
Prandoni P, Noventa F, Ghirarduzzi A et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S-e494S
Carrier M, Le GG, Wells PS, Rodger MA (2010) Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152:578–589
Stein PD, Matta F, Keyes DC, Willyerd GL (2012) Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med 125:478–484
Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907
Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002–2012
Hylek EM, Evans-Molina C, Shea C et al (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696
Heneghan C, Ward A, Perera R et al (2012) Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379:322–334
Witt DM, Sadler MA, Shanahan RL et al (2005) Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127:1515–1522
Eichinger S, Heinze G, Jandeck LM, Kyrle PA (2010) Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121:1630–1636
Hull RD, Pineo GF, Brant RF et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062–1072
Koscielny J, Beyer-Westendorf J, von Heymann C et al (2012) Risk of bleeding and haemorrhagic complication with rivaroxaban – periprocedural management of haemostasis. Hämostaseologie 32:287–293
Spannagl M, Bauersachs R, Debus ES et al (2012) Dabigatran therapy – perioperative management and interpretation of coagulation tests. Hämostaseologie 32:294–305
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709–718
The Hokusai-VTE investigators (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med [Epub ahead of print]
Buller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297
Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
Agnelli G, Buller HR, Cohen A et al; AMPLIFY Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808
Agnelli G, Buller HR, Cohen A et al (2012) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699–708
Becattini C, Agnelli G, Schenone A et al (2012) Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366:1959–1967
Brighton TA, Eikelboom JW, Mann K et al (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367:1979–1987
Aujesky D, Obrosky DS, Stone RA et al (2005) Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172:1041–1046
Jimenez D, Aujesky D, Moores L et al (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170:1383–1389
Lankeit M, Jimenez D, Kostrubiec M et al (2011) Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 124:2716–2724
Lankeit M, Friesen D, Aschoff J et al (2010) Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 31:1836–1844
Squizzato A, Galli M, Dentali F, Ageno W (2009) Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review. Eur Respir J 33:1148–1155
Aujesky D, Roy PM, Verschuren F et al (2011) Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 378:41–48
Zondag W, Mos IC, Creemers-Schild D et al (2011) Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 9:1500–1507
Agterof MJ, Schutgens RE, Snijder RJ et al (2010) Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 8:1235–1241
Otero R, Uresandi F, Jimenez D et al (2010) Home treatment in pulmonary embolism. Thromb Res 126:e1–e5
Zondag W, Kooiman J, Klok F et al (2012) Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 42:134–44
Einhaltung ethischer Richtlinien
Interessenkonflikt. S. Konstantinides erhält Vortrags-/Beraterhonorare von Bayer Vital, Boehringer Ingelheim, Bristol-Myers Squibb-Pfizer und Daiichi Sankyo. M. Lankeit erhält Vortrags-/Beraterhonorare von Pfizer Pharma GmbH und Bayer Vital. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dieser aktualisierte Beitrag erschien ursprünglich in der Zeitschrift Der Kardiologe 2013, 7:217–230. DOI 10.1007/s12181-013-0481-8. Die Teilnahme an der zertifizierten Fortbildung ist nur einmal möglich.
Rights and permissions
About this article
Cite this article
Lankeit, M., Konstantinides, S. Aktuelle Therapie und Sekundärprävention der Lungenembolie. Pneumologe 10, 443–456 (2013). https://doi.org/10.1007/s10405-013-0744-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10405-013-0744-x